AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLC
AstraZeneca, CAR-T therapies, China, Gilead Sciences, HutchMed, immuno-oncology, lung cancer, Non-small cell lung cancer, Oncology, Orpathys, savolitinib, Yescarta
0 Comment